ESMO

An expert discussed how patients with breast cancer, particularly those with a BRCA mutation, should consider future fertility and breastfeeding when making treatment decisions.

An expert discussed how liquid and tissue biopsies can help monitor treatment and detect potential resistance in patients with non-small cell lung cancer.

Through regular follow-ups and symptom assessments, breast cancer survivors have the access to physical and emotional support they may need.

An expert explained the advantages and disadvantages of radiation as a treatment for patients with renal cell carcinoma, a type of kidney cancer.

An expert discussed how the understanding of resistance mechanisms can help care teams develop a global treatment strategy for EGFR-mutated non-small cell lung cancer.

An expert discussed options young patients with breast cancer may have to preserve their fertility before starting cancer treatment.

An expert explained how radiation may be a treatment option for patients with renal cell carcinoma to manage symptoms and control the disease.

The drug combined with chemotherapy demonstrated a 60% increase in progression-free survival, suggesting signs of an FDA approval.

For patients with metastatic colorectal cancer, adding a higher dose proves just as effective as the standard dose of vitamin D3, despite one exception.

Distance relapse-free survival was maintained in patients with pMMR locally advanced rectal cancer through non-operative management of the disease.

Receiving perioperative Opdivo for non-small cell lung cancer showed event-free survival benefits compared with placebo.

Among patients with HR+/HER2+ breast cancer, Herceptin and Perjeta plus endocrine therapy proved to be beneficial without chemotherapy.

Keytruda continued to improve survival versus Yervoy in unresectable stage 3 or 4 melanoma in long-term follow-up data.

Fotivda monotherapy may show better outcomes in second-line therapy than the combination of Opdivo and Fotivda in metastatic kidney cancer.

Benmelstobart plus anlotinib significantly improved survival versus Sutent in the first-line treatment of advanced renal cell carcinoma.

Patients with stage 4 non-small cell lung cancer may derive an equal benefit with a lower dose of Keytruda versus the standard dose.

Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.

A Lynparza/cediranib combo had similar results versus standalone Lynparza among patients with relapsed platinum-sensitive ovarian cancer.

In patients with unresectable liver cancer, treatment with Imjudo plus Imfinzi showed better survival outcomes compared with Nexavar.

Findings from the CheckMate 067 of patients with advanced melanoma include the longest follow-up of a checkpoint inhibitor in any tumor type.

Krazati’s benefits were seen regardless of baseline brain metastases, researchers have reported in findings from the KRYSTAL-12 trial.

Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of subgroups.

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer.

Enhertu improved the time it took for patients with a breast cancer subset to experience worsening pain and other symptoms, without affecting overall quality of life.

At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer.

The 12-month survival rates in patients with non-clear cell renal cell carcinoma showed improvements after treatment with Yervoy plus Opdivo.

First-time treatment with Lenvima continues to outperform other treatments for thyroid cancer.

In patients with BRAF V600E-mutant metastatic colorectal cancer, a combination of Braftovi, Erbitux and chemotherapy showed promising antitumor activity.

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.